Infertility Clinical Trial
Official title:
Global Study of Women's Health
Verified date | November 26, 2012 |
Source | National Institutes of Health Clinical Center (CC) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Endometriosis, a condition in which the lining of the uterus grows on nearby tissues, is a
common condition that affects women of reproductive age worldwide. The diagnosis of
endometriosis is usually made at surgery. The most common symptom is pelvic pain. This pain
may occur at the same time as menstrual bleeding, at other times of the cycle, or during or
after sexual intercourse. Previous studies reveal the diagnosis of endometriosis is often
delayed between 8 and 12 years after the first symptoms. Women with chronic pelvic pain
report a lower quality of life. No studies, however, have been conducted to assess whether
women with endometriosis-related pelvic pain are affected differently than those with pelvic
pain from other or no identifiable causes.
This large-scale study is designed to gather prospective epidemiological data on the impact
of and risk factors for endometriosis across countries worldwide. A study of this scale and
scope has never been performed; it is anticipated that the study will provide novel insights
into the effects of the condition and associated symptoms on women s lives across different
countries, as well as explore differences in the effects of various potential risk factors.
This is an international study conducted at more than 20 sites worldwide and coordinated by
Oxford University in the United Kingdom. At the National Institutes of Health, 250
premenopausal women between 18 and 45 years of age who are having their first diagnostic
laparoscopy or laparoscopy for tubal sterilization will participate. None will have had a
prior diagnosis of endometriosis through surgery. Women will be informed about the study when
their laparoscopy is scheduled.
Procedures
- Patient completion of an online questionnaire before scheduled surgery. The following
will be assessed by the questionnaire:
- Quality of life
- General gynecologic and medical history
- Family history
- General information
- Use of health care services
- Risk factors
- Surgeon completion of questionnaire about surgical findings.
- Follow-up: Women who consent will be contacted every 1 2 years.
Status | Completed |
Enrollment | 1459 |
Est. completion date | November 26, 2012 |
Est. primary completion date | |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 18 Years to 45 Years |
Eligibility |
- INCLUSION CRITERIA: A patient who meets all of the following criteria is eligible for the study: 1. Premenopausal female 18 to 45 years of age 2. Attending for her first diagnostic laparoscopy or for laparoscopy for tubal sterilisation 3. Has no previous history of endometriosis diagnosis through surgery EXCLUSION CRITERIA: A patient who meets any of the following criteria is ineligible for the study: 1. Already has a surgically-confirmed diagnosis of endometriosis 2. Aged less than18 or greater than 45 3. Aged 18-45 but post-menopausal |
Country | Name | City | State |
---|---|---|---|
United States | National Institutes of Health Clinical Center, 9000 Rockville Pike | Bethesda | Maryland |
Lead Sponsor | Collaborator |
---|---|
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Impact of endometriosis among women worldwide | |||
Secondary | Provide a frame-work for future studies of women diagnosed with endometriosis which collect long term quality of life issues as well as personal and economic costs of endometriosis. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03607409 -
Role of Inhibin A as Biomarker for Ovarian Response for IVF Treatment
|
||
Recruiting |
NCT02312076 -
GnRHa for Luteal Phase Support in Long GnRHa Protocol Cycles
|
Phase 4 | |
Terminated |
NCT02161861 -
Improvement of IVF Fertilization Rates, by the Cyclic Tripeptide FEE - Prospective Randomized Study
|
N/A | |
Completed |
NCT03287479 -
Comparison of a Semi-automated Closed Vitrification System (Gavi®) With a Manual Open Vitrification Sytem (Cryotop®)
|
N/A | |
Terminated |
NCT03522350 -
Randomized Trial Comparing EmbryoScope With EmbryoScope+.
|
N/A | |
Completed |
NCT04496284 -
Embryo Transfer Outcomes After Vitrification With Slush Nitrogen Compared to Liquid Nitrogen
|
N/A | |
Completed |
NCT03623659 -
pArtiaL zonA pelluciDa Removal by assisteD hatchINg of Blastocysts
|
N/A | |
Completed |
NCT03895099 -
New Ovarian Stimulation With Random Start, Use of Progestin Protocol for Oocyte Donors
|
Phase 3 | |
Active, not recruiting |
NCT04142112 -
Randomized, Standard-Controlled, Study to Evaluate the Ohana IVF Sperm Preparation Kit, SPeRtility IVF Next Generation
|
N/A | |
Completed |
NCT03152643 -
Cumulative Live Birth Rates After Cleavage-stage Versus Blastocyst-stage Embryo Transfer
|
N/A | |
Recruiting |
NCT03683771 -
Assessment of Endometrial Pattern and Sub-endometrial Vascularity in ICSI Outcome
|
||
Recruiting |
NCT03161119 -
Comparing Two Different Embryo Transfer Catheters
|
N/A | |
Completed |
NCT04108039 -
Micronized Progesterone vs Gonadotropin-releasing Hormone (GnRH) Antagonist in Freeze-all IVF Cycles.
|
N/A | |
Completed |
NCT03678571 -
Oocyte Vitrification Aided With Latrunculin A
|
N/A | |
Completed |
NCT03678584 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Chaetoglobosin A ( ICSI-CA)
|
N/A | |
Completed |
NCT03678597 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Latrunculin B ( ICSI-LB)
|
N/A | |
Completed |
NCT03678558 -
Oocyte Vitrification Aided With Cytochalasin B
|
N/A | |
Completed |
NCT03677492 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Cytochalasin D ( ICSI-CD)
|
N/A | |
Completed |
NCT03678610 -
Handling Medium for ICSI With Ionomycin and Latrunculin A
|
N/A | |
Completed |
NCT03678818 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Latrunculin A (ICSI-LA)
|
N/A |